IONIS PHARMACEUTICALS INC's ticker is IONS and the CUSIP is 462222100. A total of 306 filers reported holding IONIS PHARMACEUTICALS INC in Q1 2023. The put-call ratio across all filers is 0.70 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $337 | -99.8% | 9,422 | +72.1% | 0.03% | +10.0% |
| Q2 2022 | $203,000 | -50.1% | 5,475 | -59.0% | 0.03% | -41.2% |
| Q4 2021 | $407,000 | -45.9% | 13,368 | -15.6% | 0.05% | -59.2% |
| Q3 2020 | $752,000 | +97.9% | 15,842 | +151.9% | 0.12% | +184.1% |
| Q4 2019 | $380,000 | -70.0% | 6,288 | -68.1% | 0.04% | -69.0% |
| Q2 2019 | $1,265,000 | +3.2% | 19,690 | +30.4% | 0.14% | +14.5% |
| Q1 2019 | $1,226,000 | +26.7% | 15,100 | -15.6% | 0.12% | +10.7% |
| Q4 2018 | $968,000 | -27.9% | 17,900 | -44.4% | 0.11% | +67.2% |
| Q2 2018 | $1,342,000 | -44.8% | 32,200 | -41.7% | 0.07% | -48.1% |
| Q1 2018 | $2,433,000 | +0.6% | 55,200 | +14.8% | 0.13% | -12.2% |
| Q4 2017 | $2,419,000 | +99.8% | 48,093 | +101.3% | 0.15% | +77.1% |
| Q3 2017 | $1,211,000 | +10.5% | 23,893 | +10.9% | 0.08% | +15.3% |
| Q2 2017 | $1,096,000 | +105.6% | 21,545 | +93.4% | 0.07% | +125.0% |
| Q4 2016 | $533,000 | – | 11,141 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Tweedy, Browne Co LLC | 3,510,173 | $159,221,447 | 8.52% |
| Bellevue Group AG | 9,233,700 | $418,840,632 | 6.75% |
| Deep Track Capital, LP | 2,834,069 | $128,553,370 | 4.96% |
| BVF INC/IL | 4,004,613 | $181,649,246 | 4.90% |
| Sicart Associates LLC | 203,132 | $9,214,068 | 3.61% |
| Camber Capital Management LP | 2,250,000 | $102,060 | 3.36% |
| Privium Fund Management B.V. | 228,493 | $10,364,443 | 3.08% |
| Orbimed Advisors | 2,169,500 | $98,408,520 | 2.09% |
| SECTOR GAMMA AS | 165,616 | $7,512,342 | 1.92% |
| TANAKA CAPITAL MANAGEMENT INC | 14,612 | $663 | 1.89% |